Liver Cirrhosis Research Today is a free monthly online journal that collates and summarizes the latest research about Liver Cirrhosis, including details on alcohol, treatment, drugs, effects, causes.

Volume 2 (2005), Issue 7 (July)

1. Nutritional status and serum cytokine profiles in children, adolescents, and young adults with Schistosoma japonicum-associated hepatic fibrosis, in Leyte, Philippines.
   J Infect Dis, 192(3): 528-36. [Abstract] [Full-text]
2. Necrotising fasciitis: clinical features in patients with liver cirrhosis.
   Br J Plast Surg, 58(5): 702-7. [Abstract] [Full-text]
3. Assessment of sexual functions in patients with chronic liver disease.
   Int J Impot Res, 17(4): 343-5. [Abstract] [Full-text]
4. Peritoneovenous shunt as a bridge to liver transplantation.
   Am J Transplant, 5(8): 1886-92. [Abstract] [Full-text]
5. The morphology of diaphragmatic defects in hepatic hydrothorax: thoracoscopic finding.
   J Thorac Cardiovasc Surg, 130(1): 141-5. [Abstract] [Full-text]
6. Diffuse expression of heparan sulfate proteoglycan and connective tissue growth factor in fibrous septa with many mast cells relate to unresolving hepatic fibrosis of congenital hepatic fibrosis.
   Liver Int, 25(4): 817-28. [Abstract] [Full-text]
7. Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes.
   Liver Int, 25(4): 796-807. [Abstract] [Full-text]
8. Correlation of nitric oxide and atrial natriuretic peptide changes with altered cGMP homeostasis in liver cirrhosis.
   Liver Int, 25(4): 787-95. [Abstract] [Full-text]
9. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease.
   Liver Int, 25(4): 779-86. [Abstract] [Full-text]
10. Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation -- a pilot study.
    Liver Int, 25(4): 740-5. [Abstract] [Full-text]
11. The optimal timing of liver transplantation in patients with chronic cholestatic liver disease.
    Transpl Int, 18(8): 937-40. [Abstract] [Full-text]
12. Effect of liver transplantation on tuftsin activity and phagocytic activity of neutrophil granulocytes in patients with liver cirrhosis.
    Int Arch Allergy Immunol, 137(3): 258-62. [Abstract] [Full-text]
13. Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis.
    Scand J Infect Dis, 37(6): 520-2. [Abstract] [Full-text]
14. What makes an autoantigen an autoantigen?
    Ann N Y Acad Sci, 1050: 134-45. [Abstract] [Full-text]
15. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis.
    Ann Surg Oncol, 12(8): 616-28. [Abstract] [Full-text]
16. Treatment of hepatitis C in patients who have decompensated cirrhosis.
    Clin Liver Dis, 9(3): 473-86, viii. [Abstract] [Full-text]
17. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis.
    J Pharmacol Exp Ther, 314(2): 584-95. [Abstract] [Full-text]
18. The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child-Turcotte-Pugh classification in predicting outcome.
    Arch Surg, 140(7): 650-4; discussion 655. [Abstract] [Full-text]
19. Early response of alpha2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-beta independent.
    Hepatology, 42(2): 343-52. [Abstract] [Full-text]
20. rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: a new approach to attenuate liver fibrosis in rats.
    Hepatology, 42(2): 335-42. [Abstract] [Full-text]
21. Mesenteric Th1 polarization and monocyte TNF-alpha production: first steps to systemic inflammation in rats with cirrhosis.
    Hepatology, 42(2): 411-9. [Abstract] [Full-text]
22. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic.
    Hepatology, 42(2): 458-65. [Abstract] [Full-text]
23. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort.
    Hepatology, 42(2): 282-92. [Abstract] [Full-text]
24. Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis.
    Hepatology, 42(2): 273-81. [Abstract] [Full-text]
25. Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery.
    Hepatology, 42(2): 490-2. [Abstract] [Full-text]
26. Circulatory function and hepatorenal syndrome in cirrhosis.
    Hepatology, 42(2): 439-47. [Abstract] [Full-text]
27. Determining the extent of quality health care for hospitalized patients with cirrhosis.
    Hepatology, 42(2): 492-4. [Abstract] [Full-text]
28. Increased protein glycation in cirrhosis and therapeutic strategies to prevent it.
    Ann N Y Acad Sci, 1043: 718-24. [Abstract] [Full-text]
29. Effect of ribozyme against transforming growth factorbeta1 on biological character of activated HSCs.
    IUBMB Life, 57(1): 31-9. [Abstract] [Full-text]
30. Specific gene expression patterns in liver cirrhosis.
    Biochem Biophys Res Commun, 334(2): 681-8. [Abstract] [Full-text]
31. Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis.
    J Autoimmun, 25(1): 85-91. [Abstract] [Full-text]
32. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans.
    Nat Genet, 37(8): 835-43. [Abstract] [Full-text]

© 2004-2008 Liver Cirrhosis Research Today. All Rights Reserved.